Intuitive Surgical (NASDAQ:ISRG) Trading Down 0.7% Following Insider Selling

Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report)'s share price dropped 0.7% during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $581.06 and last traded at $587.43. Approximately 220,386 shares traded hands during trading, a decline of 87% from the average daily volume of 1,759,780 shares. The stock had previously closed at $591.65.

Specifically, EVP Myriam Curet sold 408 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total value of $240,618.00. Following the sale, the executive vice president now owns 353 shares in the company, valued at approximately $208,181.75. The trade was a 53.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Jamie Samath sold 269 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $590.00, for a total value of $158,710.00. Following the completion of the sale, the chief financial officer now owns 3,282 shares in the company, valued at $1,936,380. The trade was a 7.58 % decrease in their position. The disclosure for this sale can be found here.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ISRG shares. Wells Fargo & Company increased their price objective on Intuitive Surgical from $630.00 to $687.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Morgan Stanley raised Intuitive Surgical from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $522.00 to $650.00 in a report on Monday, December 2nd. Barclays increased their price target on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Bernstein Bank increased their price target on Intuitive Surgical from $655.00 to $700.00 and gave the company an "overweight" rating in a research note on Monday, January 27th. Finally, Piper Sandler restated an "overweight" rating and issued a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $613.10.

Intuitive Surgical Stock Up 0.7 %

The company has a market capitalization of $212.12 billion, a price-to-earnings ratio of 92.91, a price-to-earnings-growth ratio of 5.67 and a beta of 1.39. The stock has a 50 day moving average of $559.48 and a 200 day moving average of $519.06.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Atala Financial Inc purchased a new position in shares of Intuitive Surgical during the 4th quarter valued at $25,000. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at $26,000. Parvin Asset Management LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at $26,000. BankPlus Trust Department bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at $28,000. Finally, Hurley Capital LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.